Evidence map›Paper›PMID 38212940›Full record

SynthesisAnnals of clinical and translational neurology2024

Domain-specific cognitive impairment in multiple sclerosis: A systematic review and meta-analysis.

Katalin Lugosi, Marie A Engh, Zsolt Huszár, Péter Hegyi, Péter Mátrai, Gábor Csukly, Zsolt Molnár, Klaudia Horváth, Dóra Mátis, Zsolt Mezei

Abstract readMeta-AnalysisSystematic Review
In one paragraph

Synthesis in Annals of clinical and translational neurology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Cognitive impairment in multiple sclerosis: from phenomenology to neurobiological mechanisms.Journal of neural transmission (Vienna, Austria : 1996) · 2024
    Review
  7. Review
  8. A review of the validation of the Brief Cognitive Assessment for Multiple Sclerosis in Latin America.Multiple sclerosis journal - experimental, translational and clinical
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Katalin LugosiCentre for Translational Medicine, Semmelweis University, Üllői út 26, 1085, Budapest, Hungary.
Marie A EnghCentre for Translational Medicine, Semmelweis University, Üllői út 26, 1085, Budapest, Hungary.
Zsolt HuszárCentre for Translational Medicine, Semmelweis University, Üllői út 26, 1085, Budapest, Hungary.
Péter HegyiCentre for Translational Medicine, Semmelweis University, Üllői út 26, 1085, Budapest, Hungary.
Péter MátraiInstitute for Translational Medicine, Medical School, University of Pécs, Pécs, Hungary.
Gábor CsuklyCentre for Translational Medicine, Semmelweis University, Üllői út 26, 1085, Budapest, Hungary.
Zsolt MolnárCentre for Translational Medicine, Semmelweis University, Üllői út 26, 1085, Budapest, Hungary.
Klaudia HorváthMultiple Sclerosis Centre, Bajcsy-Zsilinszky Hospital, Maglódi út 89-91, Budapest, 1106, Hungary.
Dóra MátisCentre for Translational Medicine, Semmelweis University, Üllői út 26, 1085, Budapest, Hungary.
Zsolt MezeiDepartment of Neurology, Semmelweis University, Balassa utca 6, 1083, Budapest, Hungary.ORCID 0000-0002-3797-2191

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveMethods of cognitive measurements in multiple sclerosis (MS) are not standardized. We aimed to identify the prevalence of cognitive domain-specific impairment (DSI) in MS by using subtests of the Brief Repeatable Battery of Neuropsychological Tests (BRB-N) with analyzing different cutoff values.

methodsThe systematic review and meta-analysis were registered on PROSPERO (ID: CRD42021287004). The systematic literature search was performed via PubMed, Embase, and CENTRAL on 24 October 2021. Inclusion criteria were adults of different MS subtypes (CIS, RRMS, PPMS, and SPMS) with the condition of distinct DSI measured by BRB-N. Pediatric MS, computerized versions of BRB-N, and patients receiving steroids were excluded. Primary outcome was pooled prevalence rates of impaired patients within each cutoff and MS subtype, with 95% confidence interval, I-squared statistics for heterogeneity, and chi-squared test for subgroup differences. Risk of bias was assessed using the "JBI Quality Assessment Tool for Prevalence Studies."

resultsIn 48 eligible observational studies (n = 3431 patients), the three most prevalent thresholds were the 2.0 SD and 1.5 SD below the mean of normative values, and the score below the fifth percentile of the normative values. A progressively increasing worsening of the overall DSI was observed from CIS, moving toward RRMS, PPMS, and SPMS.

interpretationCognitive impairment is observed in all MS phenotypes, with varying degrees. Due to several potential influencing factors, our comprehensive literature review has not revealed consistent findings, and we, therefore, recommend considering a more sophisticated, "individual referencing" approach, acknowledging the diverse clinical and sociodemographic characteristics among populations and disparities in cognitive testing.

Indexed as

Cognitive DysfunctionMultiple SclerosisHumansNeuropsychological Tests

Identifiers

PMID38212940
PMCPMC10963281

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.